{
    "title": "FDA unclear if benefits of GSK multiple myeloma drug outweigh risks",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8510737/FDA-unclear-benefits-GSK-multiple-myeloma-drug-outweigh-risks.html",
    "date": "2020-07-10",
    "keywords": [
        "treatment",
        "drug",
        "mafodotin",
        "gsk",
        "july",
        "approval",
        "belantamab",
        "fda",
        "side",
        "effect",
        "document",
        "reporting",
        "london",
        "food",
        "administration",
        "friday",
        "form",
        "blood",
        "cancer",
        "review",
        "sideeffect",
        "myeloma",
        "johnson",
        "genmabs",
        "oncology",
        "portfolio",
        "meeting",
        "committee",
        "odac",
        "cornea",
        "keratopathy",
        "frequency",
        "severity",
        "lack",
        "mitigation",
        "benefitrisk",
        "profile",
        "modifying",
        "course",
        "uncertainty",
        "dose",
        "modification",
        "strategy",
        "briefing",
        "website",
        "benefit",
        "toxicity",
        "broker",
        "confidence",
        "midstage",
        "study",
        "dosage",
        "patient",
        "life",
        "trial",
        "gsk2857916",
        "alistair",
        "banerjee",
        "editing",
        "alexander",
        "smith"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}